Zacks Investment Research
11 Nov 2025, 00:57 UTC · 48w ago
Verdict
Headline leans bullish. We score TBPH +0.80 across two claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
More positive than 91% of ticker scores this week
Top 2 movers · tap to explore
What the story claims
2 claims · scored −1 bearish … +1 bullish
Theravance Biopharma reported quarterly earnings of $0.04 per share, beating the consensus estimate of a $0.03 loss.
More positive than 94% of claims this week
Theravance Biopharma's quarterly revenue reached $19.99 million, surpassing consensus estimates by 2.08% and increasing from $16.87 million year-over-year.
So whatYear-over-year revenue growth and a beat on top-line estimates support the company's growth trajectory, though the beat margin is modest.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 69% of claims this week
Which stocks this story touches
More positive than 91% of ticker scores this week
The company beat both earnings and revenue estimates with a significant earnings surprise of 233.33%.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
13m ago
+12.9%
Price agrees with the score
$17.03 vs $15.08 close before publication (Nov 10) · not market-adjusted
TBPH chart →
